CA3174065A1 - Use of compounds in the treatment of fungal infections - Google Patents

Use of compounds in the treatment of fungal infections

Info

Publication number
CA3174065A1
CA3174065A1 CA3174065A CA3174065A CA3174065A1 CA 3174065 A1 CA3174065 A1 CA 3174065A1 CA 3174065 A CA3174065 A CA 3174065A CA 3174065 A CA3174065 A CA 3174065A CA 3174065 A1 CA3174065 A1 CA 3174065A1
Authority
CA
Canada
Prior art keywords
spp
compound
pharmaceutically acceptable
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3174065A
Other languages
English (en)
French (fr)
Inventor
Karen Joy Shaw
Michael Hodges
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Basilea Pharmaceutica International AG
Original Assignee
Amplyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amplyx Pharmaceuticals Inc filed Critical Amplyx Pharmaceuticals Inc
Publication of CA3174065A1 publication Critical patent/CA3174065A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3174065A 2020-03-04 2021-03-02 Use of compounds in the treatment of fungal infections Pending CA3174065A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062985274P 2020-03-04 2020-03-04
US62/985,274 2020-03-04
PCT/US2021/020471 WO2021178406A1 (en) 2020-03-04 2021-03-02 Use of compounds in the treatment of fungal infections

Publications (1)

Publication Number Publication Date
CA3174065A1 true CA3174065A1 (en) 2021-09-10

Family

ID=77612811

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3174065A Pending CA3174065A1 (en) 2020-03-04 2021-03-02 Use of compounds in the treatment of fungal infections

Country Status (11)

Country Link
US (2) US12521406B2 (https=)
EP (1) EP4114405A4 (https=)
JP (1) JP2023516648A (https=)
KR (1) KR20220148881A (https=)
CN (1) CN115515599A (https=)
AU (1) AU2021230529B2 (https=)
BR (1) BR112022017653A2 (https=)
CA (1) CA3174065A1 (https=)
IL (1) IL296093A (https=)
MX (1) MX2022010804A (https=)
WO (1) WO2021178406A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3187268A1 (en) * 2020-06-17 2021-12-23 Amplyx Pharmaceuticals, Inc. Compounds and methods for treating fungal infections
CN116687929B (zh) * 2023-06-16 2026-04-28 山东省妇幼保健院 血根碱在制备防治临床罕见真菌相关感染性疾病药物中的应用
WO2026020112A1 (en) * 2024-07-19 2026-01-22 Sun Pharmaceutical Industries, Inc. Oral formulations of deuruxolitinib
CN119915948B (zh) * 2025-04-02 2025-07-08 天津辰欣药物研究有限公司 一种小分子真菌肌醇酰基转移酶1抑制剂原料药中致突变杂质的分析方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
EP2345641A1 (en) 2009-12-29 2011-07-20 Polichem S.A. New secondary 8-hydroxyquinoline-7-carboxamide derivatives
EP2636409A1 (en) * 2010-11-05 2013-09-11 Eisai R&D Management Co., Ltd. Combined pharmaceutical composition as antifungal agent
IL275121B2 (en) * 2017-12-07 2025-11-01 Amplyx Pharmaceuticals Inc Heterocycle substituted pyridine derivative antifungal agents
WO2020047510A1 (en) 2018-08-31 2020-03-05 Amplyx Pharmaceuticals, Inc. Compounds and methods for treating fungal infections
CA3187268A1 (en) 2020-06-17 2021-12-23 Amplyx Pharmaceuticals, Inc. Compounds and methods for treating fungal infections

Also Published As

Publication number Publication date
US20260102419A1 (en) 2026-04-16
AU2021230529A1 (en) 2022-09-29
NZ792042A (en) 2025-09-26
JP2023516648A (ja) 2023-04-20
AU2021230529B2 (en) 2024-09-05
EP4114405A4 (en) 2024-03-13
WO2021178406A1 (en) 2021-09-10
KR20220148881A (ko) 2022-11-07
US12521406B2 (en) 2026-01-13
EP4114405A1 (en) 2023-01-11
US20230102036A1 (en) 2023-03-30
CN115515599A (zh) 2022-12-23
BR112022017653A2 (pt) 2022-10-18
MX2022010804A (es) 2023-01-16
IL296093A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
US12521406B2 (en) Use of compounds in the treatment of fungal infections
JP7793681B2 (ja) 真菌感染症を処置するための化合物および方法
WO2016131100A1 (en) Methods of treating infectious diseases
US20020193369A1 (en) Antifungal compounds and uses therefor
US20050282873A1 (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases
CN110494140A (zh) 用于自闭症谱系障碍药物治疗的方法
AU2021293911B2 (en) Compounds and methods for treating fungal infections
TW202333731A (zh) 用於治療癌症之VCP/p97抑制劑
RU2805930C1 (ru) Использование соединений при лечении грибковых инфекций
Heitmann et al. Right-sided pacemaker-related endocarditis due to Acremonium species
JP7454905B2 (ja) 有効成分であるイサブコナゾール又はそのプロドラッグを含有する真菌症治療及び／又は予防剤
HK40086224A (zh) 化合物在真菌感染的治疗中的用途
RU2824066C1 (ru) Соединения и способы для лечения грибковых инфекций
HK40085944A (en) Compounds and methods for treating fungal infections
Johnson et al. Echinocandins for prevention and treatment of invasive fungal infections
TWI920017B (zh) 用於治療真菌感染之化合物及方法
US20250302821A1 (en) Synergistic antifungal composition and method
CN119522109A (zh) 用于钙调磷酸酶抑制剂的间歇性给药的组合物
Orosz Aspergillosis, why?
Beyda et al. Micafungin
HK40050392A (en) Compounds and methods for treating fungal infections
ULC et al. Pr Caspofungin Acetate for Injection

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220831

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20241022

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20241114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250129

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250218

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260106

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260205

C13 Application revived following an application revival request

Free format text: ST27 STATUS EVENT CODE: A-6-2-C10-C13-C102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUIREMENTS DEEMED COMPLIANT FOR ALL ABANDONMENT REASONS

Effective date: 20260303

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260303

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260303

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260316

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260316